SMS Lifesciences India Limited

SMSLIFE

INE320X01016

Pharmaceuticals

End-of-day quote NSE India S.E. Other stock markets 06:00:00 2024-06-19 pm EDT			5-day change	1st Jan Change
814.8 ^INR	+2.23%		+0.56%	+53.86%

May. 27	SMS Lifesciences India Limited Recommends Final Dividend for the Year 2023-24	CI
May. 27	SMS Lifesciences India Limited Reports Earnings Results for the Fourth Quarter Ended March 31, 2024	CI

SMS Lifesciences India Limited Declares Dividend for the Year 2020-21

October 01, 2021 at 05:56 am EDT

SMS Lifesciences India Limited at its 15th Annual General Meeting dated Sept 2, 202 1 declared Dividend on Equity Shares at INR 1.50 per Equity Share of face value of INR 10 each (15%) for the Year 2020-21.

Latest news about SMS Lifesciences India Limited

SMS Lifesciences India Limited Recommends Final Dividend for the Year 2023-24	May. 27	CI
SMS Lifesciences India Limited Reports Earnings Results for the Fourth Quarter Ended March 31, 2024	May. 27	CI
SMS Lifesciences India Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023	Feb. 10	CI
SMS Lifesciences India Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023	Nov. 11	CI
SMS Lifesciences India Limited Reports Earnings Results for the First Quarter Ended June 30, 2023	23-08-08	CI
SMS Lifesciences India Limited Recommends Dividend for the Year 2022-23	23-05-29	CI
SMS Lifesciences India Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2023	23-05-29	CI
SMS Lifesciences India Limited Announces Resignation of Venkafasubbarao Polluri as Independent Director from the Board and Member of Audit Committee	23-02-10	CI
SMS Lifesciences India Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2022	23-02-10	CI
CARE Affirms BBB+ Rating on SMS Lifesciences' Long-term Bank Financing; Outlook Stable	22-11-30	MT
SMS Lifesciences India Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2022	22-11-14	CI
SMS Lifesciences India Limited Approves Dividend for the Year 2021-2022	22-10-01	CI
SMS Lifesciences India Limited Proposes Dividend for Year 2021-22	22-09-08	CI
SMS Lifesciences India Limited Reports Earnings Results for the First Quarter Ended June 30, 2022	22-08-09	CI
SMS Life Sciences Telangana, India Unit Gets Establishment Inspection Report from US FDA	22-06-24	MT
SMS Lifesciences India Limited Recommends Dividend for the Financial Year 2022	22-05-28	CI
SMS Lifesciences India Limited Reports Earnings Results for the Full Year Ended March 31, 2022	22-05-28	CI
SMS Lifesciences India Limited Reports Earnings Results for the Fourth Quarter Ended March 31, 2022	22-05-28	CI
US FDA Clears SMS Lifesciences' Manufacturing Plant in Kazipally, India	22-04-10	MT
SMS Lifesciences India Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2021	22-02-11	CI
Chemwerth, Inc. acquired 10% stake in Mahi Drugs Private Limited from SMS Lifesciences India Limited.	21-11-29	CI
SMS Lifesciences India Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2021	21-11-13	CI
SMS Lifesciences India Limited Announces Executive Changes	21-11-13	CI
SMS Lifesciences India Limited Declares Dividend for the Year 2020-21	21-10-01	CI
Sms Lifesciences India Limited Announces Neelaveni Thummala as Resignation of Independent Director, Date of Cessation September 2, 2021	21-09-02	CI

Chart SMS Lifesciences India Limited

Duration

Period

More charts

Company Profile

SMS Lifesciences India Limited is an India-based company that is engaged in the business of manufacturing of active pharma ingredients (API) and their intermediates. The Company's API products include Ranitidine Hydrochloride (Form-2) USP / Ph.Eur / IP, Famotidine USP / Ph.Eur / IP, Sildenafil Citrate USP / Ph.Eur / IP, Allopurinol USP / EP / IP, Ropivacaine Hydrochloride USP / EP / IP, Dapsone USP/ EP /BP, Sibutramine Hydrochloride USP, Itraconazole USP / Ph.Eur, Fosphenytoin Sodium USP, Domperidone / Domperidone Maleate EP / IP, Brinzolamide, Tiagabine, Fosaprepitant and Albendazole, among others. The Company's manufacturing facilities are located at Kazipally and Jeedimetla, and its research and development center at Sanath Nagar in Hyderabad. The Company's wholly owned subsidiary is Mahi Drugs Private limited.

Sector

Pharmaceuticals

Calendar

2024-08-05 - Q1 2025 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Other Pharmaceuticals

	1st Jan change	Capi.
SMS LIFESCIENCES INDIA LIMITED	+53.86%	28.89M
ELI LILLY AND COMPANY	+51.92%	803B
JOHNSON & JOHNSON	-5.96%	351B
MERCK & CO., INC.	+18.69%	324B
ABBVIE INC.	+11.25%	303B
ASTRAZENECA PLC	+16.96%	243B
ROCHE HOLDING AG	+2.25%	228B
NOVARTIS AG	+11.15%	217B
AMGEN INC.	+7.21%	164B
PFIZER, INC.	-3.31%	155B